c-MYC anticorps (pSer62)

N° du produit ABIN3201011

Détail du produit anti-c-MYC anticorps

Antigène: c-MYC (MYC) (Myc Proto-Oncogene protein (MYC))

Épitope: pSer62

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp c-MYC est non-conjugé

Application: Western Blotting (WB), Immunofluorescence (IF)

Réactivité croisée (Details): Expected to react with mouse, rat from the sequence identity.

Purification: Purified

Immunogène: Synthetic peptide containing pSer62 of cMyc

Clone: 33A12E10

Isotype: IgG2b kappa

Information d'application

Indications d'application: 1. Western blotting: ~1 g/mL

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: PBS, 50 % glycerol

Agent conservateur: Azide free

Stock: -20 °C

Références pour anticorps anti-c-MYC (ABIN3201011)

Khanna, Böckelman, Hemmes, Junttila, Wiksten, Lundin, Junnila, Murphy, Evan, Haglund, Westermarck, Ristimäki: "MYC-dependent regulation and prognostic role of CIP2A in gastric cancer." dans: Journal of the National Cancer Institute, Vol. 101, Issue 11, pp. 793-805, (2009) (PubMed).

Junttila, Puustinen, Niemelä, Ahola, Arnold, Böttzauw, Ala-aho, Nielsen, Ivaska, Taya, Lu, Lin, Chan, Wang, Grènman, Kast, Kallunki, Sears, Kähäri, Westermarck: "CIP2A inhibits PP2A in human malignancies." dans: Cell, Vol. 130, Issue 1, pp. 51-62, (2007) (PubMed).

Détails sur c-MYC

Antigène: c-MYC (MYC) (Myc Proto-Oncogene protein (MYC))

Autre désignation: C-Myc (MYC Produits)

Synonymes: anticorps MRTL, anticorps MYCC, anticorps bHLHe39, anticorps c-Myc, anticorps CMYC, anticorps c-myc, anticorps C-MYC, anticorps LOC100136746, anticorps ARC, anticorps B430311C09Rik, anticorps MYC, anticorps NOP, anticorps Nop30, anticorps RNCMYC, anticorps mMyc, anticorps AU016757, anticorps Myc2, anticorps Niard, anticorps Nird, anticorps cmyc, anticorps zc-myc, anticorps c-myc II, anticorps myc-B, anticorps myc2, anticorps myc1, anticorps CMyc, anticorps zgc:55680, anticorps CG10798, anticorps D-Myc, anticorps DM, anticorps DMYc, anticorps Dm, anticorps Dmel\CG10798, anticorps Dmyc, anticorps EG:BACN5I9.1, anticorps anon-WO03040301.171, anticorps bHLHe57, anticorps c-MYC, anticorps d-myc, anticorps dMYC, anticorps dMyc, anticorps dMyc1, anticorps da, anticorps dm, anticorps dm/dMyc, anticorps dm/myc, anticorps dmyc, anticorps dmyc1, anticorps l(1)G0139, anticorps l(1)G0354, anticorps l(1)G0359, anticorps myc, anticorps MYC proto-oncogene, bHLH transcription factor, anticorps v-myc myelocytomatosis viral oncogene homolog, anticorps nucleolar protein 3 (apoptosis repressor with CARD domain), anticorps myelocytomatosis oncogene, anticorps MYC proto-oncogene, bHLH transcription factor a, anticorps MYC proto-oncogene, bHLH transcription factor L homeolog, anticorps MYC proto-oncogene, bHLH transcription factor S homeolog, anticorps v-myc myelocytomatosis viral oncogene homolog (avian), anticorps MYC proto-oncogene, bHLH transcription factor b, anticorps CG10798 gene product from transcript CG10798-RB, anticorps MYC, anticorps LOC100136746, anticorps Nol3, anticorps Myc, anticorps myca, anticorps myc.L, anticorps myc.S, anticorps mycb

Sujet: CMyc is a proto-oncogene, which is overexpressed in a wide range of human cancers. Myc gene encodes a transcription factor that regulates a great number of genes through binding on Enhancer Box sequences (E-boxes) and recruiting histone acetyltransferase. It can also act as a transcriptional repressor. It regulates cell growth, apoptosis, differentiation and stem cell self-renewal. Previous studies on the phosphorylation of c-Myc have suggested functional association between phosphorylation at Thr58/Ser62 by glycogen synthase kinase 3, cyclin dependent kinase, ERK2 and C-Jun N terminal Kinase (JNK), cell proliferation and cell cycle regulation. Phosphorylation at Ser62 is required for Ras-induced stabilization and is prerequisite for phosphorylation at Thr58 for its degradation.

UniProt: P01106

Pathways: Signalisation p53, Cycle Cellulaire, Sensory Perception of Sound, Transition Metal Ion Homeostasis, Mitotic G1-G1/S Phases, Positive Regulation of Endopeptidase Activity, Regulation of Carbohydrate Metabolic Process, Positive Regulation of Response to DNA Damage Stimulus, L'effet Warburg